CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • TVTX Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Travere Therapeutics (TVTX) News and press releases

Company Profile

News

From Benzinga Pro
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
31 Jan 23
Biotech, News, Small Cap, FDA, Top Stories, General
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
The Latest Analyst Ratings for Travere Therapeutics
30 Jan 23
Analyst Ratings
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $40
30 Jan 23
News, Price Target, Analyst Ratings
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $33 to $40.
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $42
11 Jan 23
News, Price Target, Analyst Ratings
Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $38 to $42.
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
14 Dec 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Stifel Initiates Coverage On Travere Therapeutics with Hold Rating, Announces Price Target of $22
14 Dec 22
News, Price Target, Initiation, Analyst Ratings
Stifel analyst Alex Thompson initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Hold rating and announces Price Target of $22.
Stocks That Hit 52-Week Lows On Monday
12 Dec 22
Options
Monday saw 196 companies set new 52-week lows.
4 Analysts Have This to Say About Travere Therapeutics
5 Dec 22
Analyst Ratings
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
5 Dec 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Where Travere Therapeutics Stands With Analysts
5 Dec 22
Analyst Ratings
Wells Fargo Initiates Coverage On Travere Therapeutics with Overweight Rating, Announces Price Target of $28
5 Dec 22
News, Price Target, Initiation, Analyst Ratings
Wells Fargo initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Overweight rating and announces Price Target of $28.
Stocks That Hit 52-Week Lows On Tuesday
22 Nov 22
News, Options
During Tuesday's trading, 160 companies set new 52-week lows.

Press releases

From Benzinga Pro
Travere Therapeutics to Present at Upcoming Investor Conferences
8 Feb 23
News, Press Releases
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities Global Biopharma
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 23
Press Releases
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
News, Press Releases
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Dec 22
Press Releases
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on December 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Nov 22
Markets, Press Releases
SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn